Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape

May 8th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

Dr. Kapoor on Advice for Oncologists Treating Patients With Myeloma

May 4th 2017

Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 2nd 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

EU Approves Daratumumab Triplets for Myeloma

May 1st 2017

The European Commission has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.

Novel Agents for Multiple Myeloma

April 28th 2017

Emerging Combination Therapies for Myeloma

April 28th 2017

Therapy Choice at Myeloma Progression

April 28th 2017

Treatment for Relapsed/Refractory Multiple Myeloma

April 28th 2017

Patient Selection for Ixazomib in Myeloma

April 28th 2017

Proteasome Inhibitor Use in Myeloma

April 28th 2017

EU Approval of Ixazomib for Relapsed/Refractory Myeloma

April 28th 2017

Defining Progression in Multiple Myeloma

April 28th 2017

Early versus Late Response in Multiple Myeloma

April 28th 2017

Maintenance Therapy in Multiple Myeloma

April 28th 2017

Transplant Timing in Multiple Myeloma

April 28th 2017

Upfront Therapy for Myeloma; Impact on Choice at Relapse

April 28th 2017

The Ever-Changing Landscape of Myeloma Therapy

April 28th 2017

Dr. Kumar on Recent Advancements in the Field of Multiple Myeloma

April 27th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses some of the recent advancements, including FDA approvals, in the field of multiple myeloma.

Kite Unveils Novel BCMA-Directed CAR T-cell Therapy

April 21st 2017

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Dr. Usmani on Combining Daratumumab for Multiple Myeloma

April 20th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.